MRK logoMRK
Merck & Co Inc

25,141
Loading...
Loading...
News
all
press releases
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
Zacks·2d ago
News Placeholder
More News
News Placeholder
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.
Zacks·2d ago
News Placeholder
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
Merck (MRK) concluded the recent trading session at $85.11, signifying a +1.28% move from its prior day's close.
Zacks·3d ago
News Placeholder
Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?
Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.
Zacks·3d ago
News Placeholder
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
Zacks·3d ago
News Placeholder
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.
Stocktwits·3d ago
News Placeholder
Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50
The Financial Times reported on Wednesday that the drugmaker scrapped the research centre in King’s Cross, which was due to open in 2027, and will instead move research activity to existing sites.
Stocktwits·4d ago
News Placeholder
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
Zacks·4d ago
News Placeholder
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
Zacks·5d ago
News Placeholder
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Zacks·5d ago

Latest MRK News

View

Advertisement. Remove ads.

Advertisement. Remove ads.